AUTL · Autolus Therapeutics plc

The thesis

Autolus Therapeutics' recovery case depends on AUCATZYL sales supporting its $140–150 million 2026 revenue guidance, and the shares have drifted further from it: the 21 October 2026 close was $1.62, against $1.77 on 8 October 2026 and $1.85 on 25 September 2026. The third-quarter report, which the company had not dated as of 22 October 2026 and which the prior two quarterly reports suggest lands in mid-November, settles whether sales hold.

The narrative is maturing: the story is well known and interest has slowed since the 11 August 2026 second-quarter report. The 10 November 2026 lupus poster at the American College of Rheumatology (ACR) Convergence meeting is the other dated event. It updates an early-stage trial and is not a revenue event. Rating stays low because no new company result, guidance change or filing has appeared since the last note.

Bullish and bearish views on Autolus Therapeutics plc

The bull case on Autolus Therapeutics plc (AUTL), in brief: AUCATZYL sales beat the estimate. The bear case: The shares keep falling.

Bull case

• AUCATZYL sales beat the estimate. Autolus reported $45.689 million of second-quarter 2026 net product revenue on 11 August 2026, against a $34.016 million consensus cited by Benzinga. The company affirmed $140–150 million of full-year guidance, raised on 3 August 2026 from $120–135 million.
• Manufacturing margin improved. Second-quarter gross margin was 55% versus 6% in the first quarter, per the 11 August 2026 results. Management attributed the change to lower manufacturing cost per batch at higher volume.
• Funding runs into 2028. Autolus reported $201.6 million of cash, equivalents and marketable securities at 30 June 2026 and a new $250 million credit facility. The company says this funds operations into the second quarter of 2028.
• Lupus data are due in November. Autolus announced on 5 October 2026 that updated Phase 1 CARLYSLE data in severe refractory systemic lupus erythematosus will appear as a poster on 10 November 2026 (abstract 2216). The earlier readout showed remission by the DORIS definition in 83% of patients and complete renal response in 50% at a median follow-up of 8.9 months.
• Analysts remain positive. HC Wainwright reiterated Buy with a $10 price target on 3 August 2026. TipRanks lists an average target of $8.52 across six analysts, range $5.00 to $12.00, as of 8 October 2026.

Bear case

• The shares keep falling. The 21 October 2026 close of $1.62 is 36.2% below the 52-week high of $2.54, and below the $1.77 close of 8 October 2026. The $2.05 weekly-close recovery marker has not been reclaimed since the shares closed at $1.88 for the week ended 11 September 2026.
• Registered warrant shares can add supply. Autolus filed a prospectus on 22 September 2026 covering resale of up to 3,500,000 American depositary shares (ADS) issuable on exercise of a Perceptive warrant.
• The company still loses money. Autolus reported a $39.1 million second-quarter 2026 net loss on 11 August 2026. A cut in 2026 AUCATZYL guidance below $140 million would remove the operating support for the case.
• Price and fundamentals have diverged. Revenue and margin beat in August, yet the shares are lower in October. The market is pricing something the second-quarter numbers do not show, which the third-quarter report has to answer.

Price setup

The adjusted close on 21 October 2026 was $1.62, 36.2% below the 52-week high of $2.54 (adjusted daily closes). The 14-day relative strength index was 35.4, down from 37.1 on 8 October 2026 and above the 26.7 of 25 September 2026, so selling has eased from the September low but resumed in October. The three-month price change was 11.7%.

A weekly close above $2.05 would put the shares back above the line that failed in September. The $1.85 line from 25 September 2026 and the $1.77 close of 8 October 2026 are both now above the price.

Crowding evidence is limited. The shares sit well below their high, so there is no wide gap above a rising moving average. The observable supply is the 3,500,000-ADS resale registration of 22 September 2026. Earnings fall inside the next 30 days, which makes the third-quarter print the event that moves the shares.

Catalysts, next 30 days

• 10 November 2026: CARLYSLE lupus poster (abstract 2216) at ACR Convergence 2026, which runs 6 November to 11 November 2026.
• ~12 November 2026, est.: Third-quarter 2026 results. The company had not confirmed the date as of 22 October 2026; the estimate rests on mid-May and mid-August timing of the prior two reports.

What would change the view

The case breaks if AUCATZYL third-quarter revenue falls below the $45.689 million second-quarter figure, if 2026 guidance drops below $140 million, or if gross margin falls materially below 55%. A daily close below $1.50 would also end it.

The case would strengthen if third-quarter revenue exceeds the second-quarter figure with margin held near 55%, and the lupus poster confirms the earlier remission and renal-response rates. A weekly close above $2.05 would show the market accepting that reading. A filing showing exercise and resale of the registered warrant shares would add supply and weaken it.

What it trades with

Autolus trades with small and mid-sized cell-therapy and Oncology & immunology companies, where financing conditions and clinical news set direction. Its own drivers are AUCATZYL launch revenue and lupus data, not the broader index. The sample of company-specific news since 22 September 2026 is a single announcement, too small to draw a conclusion about momentum.